| 1 |
34664206 | Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions. | 2021 Oct |
1 |
| 2 |
24920353 | Pharmacokinetic study of rosuvastatin in males and females. | 2015 Sep |
1 |
| 3 |
26554252 | CYP2C9 Genetic Polymorphism is a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy. | 2015 |
3 |
| 4 |
24974574 | Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. | 2014 Jun |
1 |
| 5 |
23930675 | Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. | 2013 Aug |
1 |
| 6 |
22360448 | Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. | 2012 Aug |
2 |
| 7 |
23353843 | The influence of rosuvastatin on liver microsomal CYP2C6 in hereditary hypertriglyceridemic rat. | 2012 |
1 |
| 8 |
18971317 | Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent. | 2009 Feb |
1 |
| 9 |
19354002 | Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. | 2009 |
5 |
| 10 |
16784736 | Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. | 2006 Nov |
1 |
| 11 |
15901588 | Efficacy and safety of rosuvastatin in treatment of dyslipidemia. | 2005 May 15 |
1 |
| 12 |
12451430 | The effect of fluconazole on the pharmacokinetics of rosuvastatin. | 2002 Nov |
1 |